Business Context and Reporting Period
Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 21, 2025
Reporting Period: Event-based (April 21, 2025)
The Company, an emerging growth corporation incorporated in Delaware, filed this report to announce an upcoming investor presentation. The registrant is listed on The Nasdaq Stock Market LLC under the symbol "SHPH."
Key Financial Metrics
This filing is a current report regarding a corporate event and does not contain financial statements, revenue figures, profit data, cash flow information, margin analysis, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
No material changes to financial position or operations were reported in this filing. The document serves solely to disclose the scheduling of a corporate presentation.
Outlook, Management Commentary, and Risks
Upcoming Presentation
- Event: Planet MicroCap Showcase: VEGAS 2025 (in partnership with MicroCapClub).
- Date/Time: Wednesday, April 23, 2025, at 2:30 p.m. Pacific Time (5:30 p.m. Eastern Time).
- Presenter: Dr. Anatoly Dritschilo, M.D., Chairman of the Board and Chief Scientific Officer.
Presentation Topics
- Overview and update on the ongoing Phase 2 trial of Ropidoxuridine and RT for the treatment of patients with glioblastoma.
- Advancements in the Shuttle Diagnostics subsidiary, focusing on pretreatment diagnostic blood tests and imaging agents for prostate cancer patients.
Forward-Looking Statements
The filing includes standard forward-looking statements regarding future results, strategy, and plans. Management cautions that actual results may differ materially due to known and unknown risks, uncertainties, and assumptions. The Company undertakes no obligation to update these statements except as required by law.
Investor Verification Checklist
- Verify the attendance and content of the presentation on April 23, 2025, for updates on the Phase 2 glioblastoma trial.
- Review the Company's periodic reports (10-K, 10-Q) for detailed financial data, as this 8-K contains no financial metrics.
- Monitor the progress of the Shuttle Diagnostics subsidiary regarding prostate cancer diagnostic tools.
- Confirm the status of the Interim Chief Executive Officer, Christopher Cooper, and any potential leadership changes.